| Name | Title | Contact Details |
|---|
AMB Sports and Entertainment, based in Atlanta, Georgia, is a dynamic organization under the Blank Family of Businesses, led by entrepreneur Arthur Blank. The company manages a diverse portfolio that includes professional sports teams, venues, and retail operations. Key components of AMB Sports and Entertainment include the NFLs Atlanta Falcons, the MLSs Atlanta United FC, and the Atlanta Drive GC, which is set to debut in the Tomorrow Golf League in 2025. The company operates the Mercedes-Benz Stadium, a versatile venue for sports and major events, and The Home Depot Backyard, an outdoor space for community activities. Additionally, it runs the PGA TOUR Superstore, a nationwide golf retail chain. AMBSE Ventures focuses on strategic investments in sports technology and entertainment. The organization is committed to community engagement through various initiatives, including diversity programs and large-scale events. With a dedicated leadership team and a growing workforce, AMB Sports and Entertainment continues to enhance its impact in the sports and entertainment landscape.
Johnson & Johnson is a multinational healthcare company founded in 1886 in New Brunswick, New Jersey. The company is dedicated to improving human health and well-being through its innovative products and services. Johnson & Johnson operates in three main segments. The Consumer Health segment includes popular brands like Band-Aids, Tylenol, and Johnsons baby products, offering a variety of personal care and over-the-counter medications. The Pharmaceuticals division develops prescription drugs across therapeutic areas such as immunology, infectious diseases, and oncology. Lastly, the Medical Devices segment focuses on creating and manufacturing devices and diagnostics for surgical procedures, orthopedics, and vision care. The companys products cater to a wide audience, including consumers, healthcare professionals, and medical institutions, ensuring accessibility and support for various health needs.
Richelieu is Canadas leading distributor, importer, and manufacturer of specialty hardware and complementary products - and also ranks among the top players in its specialty in North America. We are the leading driver of worldwide innovations in functional and decorative hardware. We provide manufacturers and retailers with a UNIQUE mix of more than 130,000 different items in a host of categories: decorative hardware · kitchen accessories · lighting systems · functional and decorative mouldings · functional hardware · ergonomic workstations · finishing and decorating products · high-pressure laminates · veneer sheets and edgebanding products · screws and fasteners... We take pride in serving more than 110,000 customers across North America, in two major markets: * Manufacturers o Kitchen and bathroom cabinet manufacturers o Home and office furniture manufacturers o Residential and commercial woodworking industry, etc. * Retailers o Purchasing groups o Small and medium-sized hardware stores o Renovation superstores 113 distribution centers in North America. Some 3,000 people work throughout the network, more than half are specialized in sales and marketing, so as to provide our extensive base of loyal customers with first-class service. Richelieu Hardware Ltd. is a public company listed on the Toronto Stock Exchange (TSX) under the ticker symbol RCH.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.